NCT03535727 - A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 21, 2018

Primary Completion Date

October 3, 2022

Study Completion Date

October 3, 2022

Conditions

AdenocarcinomaPancreatic NeoplasmsNeoplasm, GlandularNeoplasmsNeoplasms PancreaticDigestive System NeoplasmEndocrine Gland NeoplasmsDigestive System DiseasePancreatic DiseasesEndocrine System Diseases

Interventions

DRUG

Nab-paclitaxel

IV over 30 minutes; Days 1 and 15

DRUG

Gemcitabine

IV over 30 minutes; Days 1 and 15

DRUG

Capecitabine

PO twice daily (BID); Days 1-7, 15-21

DRUG

Cisplatin

IV over 60 minutes; Days 1 and 15

DRUG

Irinotecan

IV over 30 minutes; Days 1 and 15

DRUG

Nab-paclitaxel

IV over 30 minutes; Days 4 and 11

DRUG

Gemcitabine

IV over 30 minutes; Days 4 and 11

DRUG

Capecitabine

PO BID; Days 1- 14

DRUG

Cisplatin

IV over 60 minutes; Days 4 and 11

DRUG

Irinotecan

IV over 30 minutes; Days 4 and 11

Trial Locations (1)

21231

Sidney Kimmel Comprehensive Cancer Center, Baltimore

All Listed Sponsors

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER